Skip to main navigation

Careers    |    Contact    |    News    |   

  • About Arbutus
    • Overview
    • Management
    • Our Board
    • Scientific Advisory Board
    • Careers
  • About HBV
    • HBV Background
    • HBV Science
    • The Baruch S. Blumberg Institute
  • >
  • R&D Portfolio
    • HBV Assets
      • AB-729 (GalNAc-RNAi)
      • AB-836 (Oral Capsid Inhibitor)
      • AB-101 (Oral PD-L1 Inhibitor)
      • AB-161 (Oral HBV RNA Destabilizers)
    • Coronavirus
  • Partners
    • Partnering & Licensing
    • Collaborations & Partners
  • Investors
    • Investor Center
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Investor FAQ
    • Contact Us

Investor Relations

  • Investor Center
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Press Releases
  • Events & Presentations
  • Investor FAQ
  • Contact Us

SEC Filing Details

Document Details

Form
10-K
Filing Date
Mar 3, 2022
Document Date
Dec 31, 2021
Form Description
Annual report which provides a comprehensive overview of the company for the past year
Filing Group
Annual Filings
Company
Arbutus Biopharma Corporation
Issuer
ARBUTUS BIOPHARMA CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT

Shareholder Tools

  • Email Alerts Email Alerts
  • RSS News Feeds RSS News Feeds
  • Download Library Download Library

© 2022 Arbutus Biopharma

Legal Terms